ALTERITY THERAPEUTICS LIMITED - Announcements

3.57%

1.4¢

Market Cap $128.9M

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	30/10/20	353.74KB	Share
ATH	MSA patients enrolled in bioMUSE Study	PRICE SENSITIVE	27/10/20	184.03KB	Share
ATH	Alterity completes Placement Tranche 1 raising $10M	PRICE SENSITIVE	23/10/20	205.61KB	Share
ATH	Alterity raises $35M in placement to institutional investors	PRICE SENSITIVE	16/10/20	234.89KB	Share
ATH	Trading Halt	PRICE SENSITIVE	12/10/20	164.99KB	Share
ATH	Form 20-F	PRICE SENSITIVE	16/09/20	2.41MB	Share
ATH	Company update on Annual Report 2020	PRICE SENSITIVE	09/09/20	177.51KB	Share
ATH	Preliminary Final Report	PRICE SENSITIVE	31/08/20	513.84KB	Share
ATH	New data independently confirms safety profile of ATH434	PRICE SENSITIVE	04/08/20	229.39KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	30/07/20	375.42KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	01/07/20	1003.48KB	Share
ATH	Pause in Trading	PRICE SENSITIVE	01/07/20	115.98KB	Share
ATH	Meeting with US FDA provides development path for ATH434	PRICE SENSITIVE	30/06/20	210.21KB	Share
ATH	Presentation on ATH434 to American Academy of Neurology	PRICE SENSITIVE	21/05/20	203.75KB	Share
ATH	Appendix 4C and Quarterly Update	PRICE SENSITIVE	30/04/20	345.52KB	Share
ATH	NASDAQ Temporary Relief	PRICE SENSITIVE	22/04/20	193.8KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	432.22KB	Share
ATH	NASDAQ Non-Compliance Notice Received	PRICE SENSITIVE	07/02/20	217.47KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	372.04KB	Share
ATH	Alterity receives a $4.8 million R&D Tax Incentive Refund	PRICE SENSITIVE	15/01/20	150.88KB	Share
ATH	European Orphan Designation granted for PBT434 for MSA	PRICE SENSITIVE	14/01/20	154.13KB	Share
ATH	AGM Presentation 2019	PRICE SENSITIVE	26/11/19	776.76KB	Share
ATH	Chairman's Address to Shareholders	PRICE SENSITIVE	26/11/19	155.78KB	Share
ATH	Lead drug candidate receives positive opinion from EMA	PRICE SENSITIVE	18/11/19	153.3KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/19	346.34KB	Share
ATH	Appendix 4E & Annual Report 2019	PRICE SENSITIVE	30/08/19	1.69MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	373.15KB	Share
ATH	Successful Completion of Phase 1 Clinical Trial	PRICE SENSITIVE	29/07/19	203.92KB	Share
ATH	Prospectus filed pursuant to SEC Rule 424(b)(3)	PRICE SENSITIVE	23/05/19	441.28KB	Share
ATH	Alterity presents initial Phase 1 clinical trial data at AAN	PRICE SENSITIVE	06/05/19	720.93KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	17/04/19	160.57KB	Share
ATH	Prana receives A$3.3 million R&D Tax Incentive Refund	PRICE SENSITIVE	18/03/19	214.95KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	217.91KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	249.91KB	Share
ATH	Orphan Designation for PBT434 for treatment of MSA	PRICE SENSITIVE	31/01/19	134KB	Share
ATH	Life Bioscience LLC leads strategic investment upto A$44.5M	PRICE SENSITIVE	28/12/18	235.93KB	Share
ATH	Trading Halt	PRICE SENSITIVE	24/12/18	458.83KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/18	189.64KB	Share
ATH	New data show potential for PBT434 to treat MSA	PRICE SENSITIVE	05/10/18	698.02KB	Share
ATH	Preliminary Final Report	PRICE SENSITIVE	31/08/18	2.42MB	Share
ATH	Annual Report to shareholders	PRICE SENSITIVE	31/08/18	2.35MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	262.22KB	Share
ATH	Prana to present PBT434 data at International Congress	PRICE SENSITIVE	09/07/18	751.56KB	Share
ATH	First Volunteers Dosed in Phase I Clinical Trial of PBT434	PRICE SENSITIVE	04/07/18	209.53KB	Share
ATH	Prana to commence Phase 1 clinical trial of PBT434	PRICE SENSITIVE	14/06/18	716.14KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/18	279.83KB	Share
ATH	PBT434 at the 6th International Multiple System Atrophy Conf	PRICE SENSITIVE	06/03/18	637.33KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/18	275.48KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/18	698.63KB	Share
ATH	Prana receives $3 million R&D Tax Incentive Refund	PRICE SENSITIVE	19/12/17	609.71KB	Share
ATH	Prospectus Supplement	PRICE SENSITIVE	09/11/17	148.88KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/17	697.57KB	Share
ATH	Notice of Meeting/ Proxy Form	PRICE SENSITIVE	13/10/17	12.69MB	Share
ATH	Form F-3	PRICE SENSITIVE	11/10/17	246.36KB	Share
ATH	Appendix 4E and Annual Report	PRICE SENSITIVE	31/08/17	2.09MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/17	697.27KB	Share
ATH	Prana commences research collaboration with Takeda	PRICE SENSITIVE	18/07/17	618.4KB	Share
ATH	PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration	PRICE SENSITIVE	03/07/17	687.1KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/17	52.36KB	Share
ATH	PBT434 presented at 13th International AD/PD Conference	PRICE SENSITIVE	30/03/17	371.7KB	Share
ATH	Half Year Accounts	PRICE SENSITIVE	24/02/17	281.58KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/17	282.44KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	09/01/17	472.31KB	Share
ATH	Business Update	PRICE SENSITIVE	23/12/16	445.25KB	Share
ATH	Prana provides regulatory update for PBT2-PBT.AX	PRICE SENSITIVE	03/11/16	92.66KB	Share
ATH	Prana provides regulatory update for PBT2	PRICE SENSITIVE	03/11/16	92.66KB	Share
ATH	Prana announces $4.8 million R&D refund-PBT.AX	PRICE SENSITIVE	31/10/16	464.26KB	Share
ATH	Appendix 4C - quarterly-PBT.AX	PRICE SENSITIVE	31/10/16	281.69KB	Share
ATH	New Reach2HD data presented at American Neurological Assoc.-PBT.AX	PRICE SENSITIVE	18/10/16	97.57KB	Share
ATH	Preliminary Final Report-PBT.AX	PRICE SENSITIVE	28/08/16	685.9KB	Share
ATH	Preliminary Final Report-PBT.AX	PRICE SENSITIVE	26/08/16	685.9KB	Share
ATH	Response to ASX Price Query-PBT.AX	PRICE SENSITIVE	10/08/16	673.18KB	Share
ATH	Appendix 4C - quarterly-PBT.AX	PRICE SENSITIVE	27/07/16	262.02KB	Share
ATH	Response to ASX Price Query-PBT.AX	PRICE SENSITIVE	14/06/16	525.35KB	Share
ATH	Prana announces $6.5 million R&D refund-PBT.AX	PRICE SENSITIVE	09/05/16	370.48KB	Share
ATH	Appendix 4C - quarterly-PBT.AX	PRICE SENSITIVE	29/04/16	193.05KB	Share
ATH	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/16	1.18MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/16	195.2KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/15	192.77KB	Share
ATH	Appendix 4E and Annual Report 2015	PRICE SENSITIVE	26/08/15	8.18MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/15	53.36KB	Share
ATH	Safety Outcomes of Alzheimer's IMAGINE Extension Trial	PRICE SENSITIVE	30/06/15	379.06KB	Share
ATH	Prana announces $6.8 million R&D refund	PRICE SENSITIVE	19/06/15	89.39KB	Share
ATH	Approval of PBT2 Orphan Designation for Huntingtons Disease	PRICE SENSITIVE	01/06/15	378.16KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	22/05/15	307.84KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/15	76.21KB	Share
ATH	PBT2 recommended for orphan designation in Europe	PRICE SENSITIVE	28/04/15	138.69KB	Share
MPL +3PL AAC AAX ABY TSN ACO ACX AFA AFJ AGO AMI ANG APO ASH ASZ ATR AVG AWN AXZ AZZ BAL BCI BDR BGG BLA BLX BRL BYI CGW PRG COF AEL CPL CTD CTP CUV CVN CYG MCM DSH E88 EAX EHE EHL ELD K2P EML ENN FAR FML FPH TOY FWD GBG GBT GEG GFY ETM GMF GNE GNG GOR GOW GDA HCH HFR HGO HSN HUO HZN A1M ILU IMD IPD IPH IQE ISN IWG JIN LAU VBC LHC LOV LYC LYL FDM MDL MFG MGX MIG MIN MND MXI NAN NHF NTU NWF NWT WFL OCL OML PAN ATH PEN PGR PHI PME POS PSQ HYD REG RFF RHP RSG RUL SDA SDL SEK SFX SHJ SHV SIO SIQ SLX SOM SRF SYR TGA TIG TOF TRY TZN UBN VET VLW WLF WOR ZSP	S&P DJ Indices Announces March Quarterly Review	PRICE SENSITIVE	06/03/15	100.19KB	Share
ATH	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/15	1.59MB	Share
ATH	FDA End-of Phase 2 Status Update	PRICE SENSITIVE	13/02/15	86.25KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	53.24KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	12/12/14	209.06KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/14	58.16KB	Share
ATH	FDA Orphan Drug Designation for PBT2 for Huntington Disease	PRICE SENSITIVE	05/09/14	85.36KB	Share
ATH	Trading Halt	PRICE SENSITIVE	05/09/14	78.26KB	Share
ATH	Appendix 4E & Preliminary Final Report	PRICE SENSITIVE	29/08/14	406.74KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/14	81.25KB	Share
ATH	Prana Alzheimers disease Development Program update	PRICE SENSITIVE	17/07/14	3.56MB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	28/05/14	191.62KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/14	71.28KB	Share

ATH Appendix 4C and Quarterly Cash Flow Report
30/10/20	PRICE SENSITIVE	353.74KB	Share
ATH MSA patients enrolled in bioMUSE Study
27/10/20	PRICE SENSITIVE	184.03KB	Share
ATH Alterity completes Placement Tranche 1 raising $10M
23/10/20	PRICE SENSITIVE	205.61KB	Share
ATH Alterity raises $35M in placement to institutional investors
16/10/20	PRICE SENSITIVE	234.89KB	Share
ATH Trading Halt
12/10/20	PRICE SENSITIVE	164.99KB	Share
ATH Form 20-F
16/09/20	PRICE SENSITIVE	2.41MB	Share
ATH Company update on Annual Report 2020
09/09/20	PRICE SENSITIVE	177.51KB	Share
ATH Preliminary Final Report
31/08/20	PRICE SENSITIVE	513.84KB	Share
ATH New data independently confirms safety profile of ATH434
04/08/20	PRICE SENSITIVE	229.39KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
30/07/20	PRICE SENSITIVE	375.42KB	Share
ATH Response to ASX Price Query
01/07/20	PRICE SENSITIVE	1003.48KB	Share
ATH Pause in Trading
01/07/20	PRICE SENSITIVE	115.98KB	Share
ATH Meeting with US FDA provides development path for ATH434
30/06/20	PRICE SENSITIVE	210.21KB	Share
ATH Presentation on ATH434 to American Academy of Neurology
21/05/20	PRICE SENSITIVE	203.75KB	Share
ATH Appendix 4C and Quarterly Update
30/04/20	PRICE SENSITIVE	345.52KB	Share
ATH NASDAQ Temporary Relief
22/04/20	PRICE SENSITIVE	193.8KB	Share
ATH Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	432.22KB	Share
ATH NASDAQ Non-Compliance Notice Received
07/02/20	PRICE SENSITIVE	217.47KB	Share
ATH Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	372.04KB	Share
ATH Alterity receives a $4.8 million R&D Tax Incentive Refund
15/01/20	PRICE SENSITIVE	150.88KB	Share
ATH European Orphan Designation granted for PBT434 for MSA
14/01/20	PRICE SENSITIVE	154.13KB	Share
ATH AGM Presentation 2019
26/11/19	PRICE SENSITIVE	776.76KB	Share
ATH Chairman's Address to Shareholders
26/11/19	PRICE SENSITIVE	155.78KB	Share
ATH Lead drug candidate receives positive opinion from EMA
18/11/19	PRICE SENSITIVE	153.3KB	Share
ATH Appendix 4C - quarterly
30/10/19	PRICE SENSITIVE	346.34KB	Share
ATH Appendix 4E & Annual Report 2019
30/08/19	PRICE SENSITIVE	1.69MB	Share
ATH Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	373.15KB	Share
ATH Successful Completion of Phase 1 Clinical Trial
29/07/19	PRICE SENSITIVE	203.92KB	Share
ATH Prospectus filed pursuant to SEC Rule 424(b)(3)
23/05/19	PRICE SENSITIVE	441.28KB	Share
ATH Alterity presents initial Phase 1 clinical trial data at AAN
06/05/19	PRICE SENSITIVE	720.93KB	Share
ATH Appendix 4C - quarterly
17/04/19	PRICE SENSITIVE	160.57KB	Share
ATH Prana receives A$3.3 million R&D Tax Incentive Refund
18/03/19	PRICE SENSITIVE	214.95KB	Share
ATH Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	217.91KB	Share
ATH Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	249.91KB	Share
ATH Orphan Designation for PBT434 for treatment of MSA
31/01/19	PRICE SENSITIVE	134KB	Share
ATH Life Bioscience LLC leads strategic investment upto A$44.5M
28/12/18	PRICE SENSITIVE	235.93KB	Share
ATH Trading Halt
24/12/18	PRICE SENSITIVE	458.83KB	Share
ATH Appendix 4C - quarterly
30/10/18	PRICE SENSITIVE	189.64KB	Share
ATH New data show potential for PBT434 to treat MSA
05/10/18	PRICE SENSITIVE	698.02KB	Share
ATH Preliminary Final Report
31/08/18	PRICE SENSITIVE	2.42MB	Share
ATH Annual Report to shareholders
31/08/18	PRICE SENSITIVE	2.35MB	Share
ATH Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	262.22KB	Share
ATH Prana to present PBT434 data at International Congress
09/07/18	PRICE SENSITIVE	751.56KB	Share
ATH First Volunteers Dosed in Phase I Clinical Trial of PBT434
04/07/18	PRICE SENSITIVE	209.53KB	Share
ATH Prana to commence Phase 1 clinical trial of PBT434
14/06/18	PRICE SENSITIVE	716.14KB	Share
ATH Appendix 4C - quarterly
27/04/18	PRICE SENSITIVE	279.83KB	Share
ATH PBT434 at the 6th International Multiple System Atrophy Conf
06/03/18	PRICE SENSITIVE	637.33KB	Share
ATH Half Yearly Report and Accounts
28/02/18	PRICE SENSITIVE	275.48KB	Share
ATH Appendix 4C - quarterly
31/01/18	PRICE SENSITIVE	698.63KB	Share
ATH Prana receives $3 million R&D Tax Incentive Refund
19/12/17	PRICE SENSITIVE	609.71KB	Share
ATH Prospectus Supplement
09/11/17	PRICE SENSITIVE	148.88KB	Share
ATH Appendix 4C - quarterly
30/10/17	PRICE SENSITIVE	697.57KB	Share
ATH Notice of Meeting/ Proxy Form
13/10/17	PRICE SENSITIVE	12.69MB	Share
ATH Form F-3
11/10/17	PRICE SENSITIVE	246.36KB	Share
ATH Appendix 4E and Annual Report
31/08/17	PRICE SENSITIVE	2.09MB	Share
ATH Appendix 4C - quarterly
27/07/17	PRICE SENSITIVE	697.27KB	Share
ATH Prana commences research collaboration with Takeda
18/07/17	PRICE SENSITIVE	618.4KB	Share
ATH PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
03/07/17	PRICE SENSITIVE	687.1KB	Share
ATH Appendix 4C - quarterly
27/04/17	PRICE SENSITIVE	52.36KB	Share
ATH PBT434 presented at 13th International AD/PD Conference
30/03/17	PRICE SENSITIVE	371.7KB	Share
ATH Half Year Accounts
24/02/17	PRICE SENSITIVE	281.58KB	Share
ATH Appendix 4C - quarterly
30/01/17	PRICE SENSITIVE	282.44KB	Share
ATH Response to ASX Price Query
09/01/17	PRICE SENSITIVE	472.31KB	Share
ATH Business Update
23/12/16	PRICE SENSITIVE	445.25KB	Share
ATH Prana provides regulatory update for PBT2-PBT.AX
03/11/16	PRICE SENSITIVE	92.66KB	Share
ATH Prana provides regulatory update for PBT2
03/11/16	PRICE SENSITIVE	92.66KB	Share
ATH Prana announces $4.8 million R&D refund-PBT.AX
31/10/16	PRICE SENSITIVE	464.26KB	Share
ATH Appendix 4C - quarterly-PBT.AX
31/10/16	PRICE SENSITIVE	281.69KB	Share
ATH New Reach2HD data presented at American Neurological Assoc.-PBT.AX
18/10/16	PRICE SENSITIVE	97.57KB	Share
ATH Preliminary Final Report-PBT.AX
28/08/16	PRICE SENSITIVE	685.9KB	Share
ATH Preliminary Final Report-PBT.AX
26/08/16	PRICE SENSITIVE	685.9KB	Share
ATH Response to ASX Price Query-PBT.AX
10/08/16	PRICE SENSITIVE	673.18KB	Share
ATH Appendix 4C - quarterly-PBT.AX
27/07/16	PRICE SENSITIVE	262.02KB	Share
ATH Response to ASX Price Query-PBT.AX
14/06/16	PRICE SENSITIVE	525.35KB	Share
ATH Prana announces $6.5 million R&D refund-PBT.AX
09/05/16	PRICE SENSITIVE	370.48KB	Share
ATH Appendix 4C - quarterly-PBT.AX
29/04/16	PRICE SENSITIVE	193.05KB	Share
ATH Appendix 4D Half Yearly Report and Accounts
25/02/16	PRICE SENSITIVE	1.18MB	Share
ATH Appendix 4C - quarterly
29/01/16	PRICE SENSITIVE	195.2KB	Share
ATH Appendix 4C - quarterly
30/10/15	PRICE SENSITIVE	192.77KB	Share
ATH Appendix 4E and Annual Report 2015
26/08/15	PRICE SENSITIVE	8.18MB	Share
ATH Appendix 4C - quarterly
27/07/15	PRICE SENSITIVE	53.36KB	Share
ATH Safety Outcomes of Alzheimer's IMAGINE Extension Trial
30/06/15	PRICE SENSITIVE	379.06KB	Share
ATH Prana announces $6.8 million R&D refund
19/06/15	PRICE SENSITIVE	89.39KB	Share
ATH Approval of PBT2 Orphan Designation for Huntingtons Disease
01/06/15	PRICE SENSITIVE	378.16KB	Share
ATH Response to ASX Price Query
22/05/15	PRICE SENSITIVE	307.84KB	Share
ATH Appendix 4C - quarterly
28/04/15	PRICE SENSITIVE	76.21KB	Share
ATH PBT2 recommended for orphan designation in Europe
28/04/15	PRICE SENSITIVE	138.69KB	Share
MPL +3PL AAC AAX ABY TSN ACO ACX AFA AFJ AGO AMI ANG APO ASH ASZ ATR AVG AWN AXZ AZZ BAL BCI BDR BGG BLA BLX BRL BYI CGW PRG COF AEL CPL CTD CTP CUV CVN CYG MCM DSH E88 EAX EHE EHL ELD K2P EML ENN FAR FML FPH TOY FWD GBG GBT GEG GFY ETM GMF GNE GNG GOR GOW GDA HCH HFR HGO HSN HUO HZN A1M ILU IMD IPD IPH IQE ISN IWG JIN LAU VBC LHC LOV LYC LYL FDM MDL MFG MGX MIG MIN MND MXI NAN NHF NTU NWF NWT WFL OCL OML PAN ATH PEN PGR PHI PME POS PSQ HYD REG RFF RHP RSG RUL SDA SDL SEK SFX SHJ SHV SIO SIQ SLX SOM SRF SYR TGA TIG TOF TRY TZN UBN VET VLW WLF WOR ZSP S&P DJ Indices Announces March Quarterly Review
06/03/15	PRICE SENSITIVE	100.19KB	Share
ATH Appendix 4D Half Yearly Report and Accounts
24/02/15	PRICE SENSITIVE	1.59MB	Share
ATH FDA End-of Phase 2 Status Update
13/02/15	PRICE SENSITIVE	86.25KB	Share
ATH Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	53.24KB	Share
ATH Response to ASX Price Query
12/12/14	PRICE SENSITIVE	209.06KB	Share
ATH Appendix 4C - quarterly
30/10/14	PRICE SENSITIVE	58.16KB	Share
ATH FDA Orphan Drug Designation for PBT2 for Huntington Disease
05/09/14	PRICE SENSITIVE	85.36KB	Share
ATH Trading Halt
05/09/14	PRICE SENSITIVE	78.26KB	Share
ATH Appendix 4E & Preliminary Final Report
29/08/14	PRICE SENSITIVE	406.74KB	Share
ATH Appendix 4C - quarterly
31/07/14	PRICE SENSITIVE	81.25KB	Share
ATH Prana Alzheimers disease Development Program update
17/07/14	PRICE SENSITIVE	3.56MB	Share
ATHResponse to ASX Price Query
28/05/14	PRICE SENSITIVE	191.62KB	Share
ATHAppendix 4C - quarterly
24/04/14	PRICE SENSITIVE	71.28KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.4¢		Change -0.001(3.57%)		Mkt cap ! $128.9M

Open	High	Low	Value	Volume
1.4¢	1.4¢	1.4¢	$3.211K	236.5K

Buyers (Bids)

No.	Vol.	Price($)
44	23945618	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	2024025	9

View Market Depth

No.	Vol.	Price($)
44	23945618	0.013
40	17483569	0.012
18	8041147	0.011
33	14989355	0.010
15	6993127	0.009

Price($)	Vol.	No.
0.014	2024025	9
0.015	21088306	13
0.016	4283104	13
0.017	7408424	11
0.018	11761167	21

Last trade - 09.59am 13/08/2025 (20 minute delay)


Last 1.3¢		Change -0.001 ( 0.00 %)
Open	High	Low	Volume
1.4¢	1.4¢	1.3¢	2314285
Last updated 10.40am 13/08/2025 ?

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available